Response to thyrotropin releasing hormone: an objective criterion for the adequacy of thyrotropin suppression therapy

D. P. Hoffman, Martin I. Surks, J. H. Oppenheimer, E. D. Weitzman

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Most serum thyrotropin (TSH) assays do not adequately discriminate between normal values and absent TSH. The authors therefore evaluated the TSH response to thyrotropin releasing hormone (TRH) as a criterion for the adequacy of TSH suppression therapy. Twenty-six outpatients with various thyroid disorders (cancer, 10; nodules, 9; miscellaneous, 4; hypothyroidism after 131I therapy for Graves' disease, 3) were studied. Using the frequent sampling technique (samples every 20 min) in two normal volunteers and one untreated patient who was TRH-responsive, the authors first confirmed the observation that TSH secretion occurred episodically throughout the 24-h period. In contrast, serum TSH was undetectable (<0.6 μU/ml) throughout the 24-h period in 5 patients on TSH suppression therapy who were TRH-unresponsive and one who had a minimal response to TRH. Thus, TRH-unresponsive patients did not secrete measurable amounts of TSH throughout the 24-h period. To suppress TSH secretion, all patients were treated with L-thyroxine (T4) at doses which resulted in undetectable TSH values in random plasma samples. TRH tests were carried out only when random TSH concentrations were <0.6 μU/ml. Seven of the 26 patients (27%) including two with thyroid cancer were TRH-responsive indicating a potential for TSH secretion. In these seven, the T4 dose was adjusted until they were TRH-unresponsive. The mean change in T4 dose of these 7 patients was 20 ± 10 (SD) μg/day and this resulted in a mean increase of 1.5 ± 1.1 μg/dl for T4 and 20 ± 20 ng/dl for T3. For all patients, the mean T4 dose required for TSH suppression was 172 ± 53 μg/day or 2.6 ± 0.8 μg per day per kg body weight. Twenty-three of 26 patients required between 100-200 μg/day and the remaining 3, 250-300 μg/day. The T4 dose required to suppress TSH resulted in normal serum concentrations of T4, 9.1 ± 2.0 μg/dl, and T3, 136.7 ± 33.6 ng/dl. These T4 doses did not produce a rapid heart rate, either awake or asleep, arrhythmias, or electrocardiographic abnormalities as assessed by 24-h Holter monitor tracings in 11 patients. Their results thus show that the T4 dose which results in an unresponsive TRH test ensures that serum TSH will remain undetectable (<0.6 μU/ml) throughout the 24-h period. An unresponsive r118w1.r128w2+ TRH test, therefore, appears to be a very useful and reliable index of TSH suppression.

Original languageEnglish (US)
Pages (from-to)892-901
Number of pages10
JournalJournal of Clinical Endocrinology and Metabolism
Volume44
Issue number5
StatePublished - 1977

Fingerprint

Thyrotropin-Releasing Hormone
Thyrotropin
Therapeutics
Serum
Thyroid Neoplasms
Graves Disease
Hypothyroidism
Thyroxine
Cardiac Arrhythmias
Assays
Healthy Volunteers
Reference Values
Outpatients
Heart Rate
Body Weight
Sampling
Plasmas

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Response to thyrotropin releasing hormone : an objective criterion for the adequacy of thyrotropin suppression therapy. / Hoffman, D. P.; Surks, Martin I.; Oppenheimer, J. H.; Weitzman, E. D.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 44, No. 5, 1977, p. 892-901.

Research output: Contribution to journalArticle

@article{217f5dc4a53341d8a0b575f0565043c5,
title = "Response to thyrotropin releasing hormone: an objective criterion for the adequacy of thyrotropin suppression therapy",
abstract = "Most serum thyrotropin (TSH) assays do not adequately discriminate between normal values and absent TSH. The authors therefore evaluated the TSH response to thyrotropin releasing hormone (TRH) as a criterion for the adequacy of TSH suppression therapy. Twenty-six outpatients with various thyroid disorders (cancer, 10; nodules, 9; miscellaneous, 4; hypothyroidism after 131I therapy for Graves' disease, 3) were studied. Using the frequent sampling technique (samples every 20 min) in two normal volunteers and one untreated patient who was TRH-responsive, the authors first confirmed the observation that TSH secretion occurred episodically throughout the 24-h period. In contrast, serum TSH was undetectable (<0.6 μU/ml) throughout the 24-h period in 5 patients on TSH suppression therapy who were TRH-unresponsive and one who had a minimal response to TRH. Thus, TRH-unresponsive patients did not secrete measurable amounts of TSH throughout the 24-h period. To suppress TSH secretion, all patients were treated with L-thyroxine (T4) at doses which resulted in undetectable TSH values in random plasma samples. TRH tests were carried out only when random TSH concentrations were <0.6 μU/ml. Seven of the 26 patients (27{\%}) including two with thyroid cancer were TRH-responsive indicating a potential for TSH secretion. In these seven, the T4 dose was adjusted until they were TRH-unresponsive. The mean change in T4 dose of these 7 patients was 20 ± 10 (SD) μg/day and this resulted in a mean increase of 1.5 ± 1.1 μg/dl for T4 and 20 ± 20 ng/dl for T3. For all patients, the mean T4 dose required for TSH suppression was 172 ± 53 μg/day or 2.6 ± 0.8 μg per day per kg body weight. Twenty-three of 26 patients required between 100-200 μg/day and the remaining 3, 250-300 μg/day. The T4 dose required to suppress TSH resulted in normal serum concentrations of T4, 9.1 ± 2.0 μg/dl, and T3, 136.7 ± 33.6 ng/dl. These T4 doses did not produce a rapid heart rate, either awake or asleep, arrhythmias, or electrocardiographic abnormalities as assessed by 24-h Holter monitor tracings in 11 patients. Their results thus show that the T4 dose which results in an unresponsive TRH test ensures that serum TSH will remain undetectable (<0.6 μU/ml) throughout the 24-h period. An unresponsive r118w1.r128w2+ TRH test, therefore, appears to be a very useful and reliable index of TSH suppression.",
author = "Hoffman, {D. P.} and Surks, {Martin I.} and Oppenheimer, {J. H.} and Weitzman, {E. D.}",
year = "1977",
language = "English (US)",
volume = "44",
pages = "892--901",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "5",

}

TY - JOUR

T1 - Response to thyrotropin releasing hormone

T2 - an objective criterion for the adequacy of thyrotropin suppression therapy

AU - Hoffman, D. P.

AU - Surks, Martin I.

AU - Oppenheimer, J. H.

AU - Weitzman, E. D.

PY - 1977

Y1 - 1977

N2 - Most serum thyrotropin (TSH) assays do not adequately discriminate between normal values and absent TSH. The authors therefore evaluated the TSH response to thyrotropin releasing hormone (TRH) as a criterion for the adequacy of TSH suppression therapy. Twenty-six outpatients with various thyroid disorders (cancer, 10; nodules, 9; miscellaneous, 4; hypothyroidism after 131I therapy for Graves' disease, 3) were studied. Using the frequent sampling technique (samples every 20 min) in two normal volunteers and one untreated patient who was TRH-responsive, the authors first confirmed the observation that TSH secretion occurred episodically throughout the 24-h period. In contrast, serum TSH was undetectable (<0.6 μU/ml) throughout the 24-h period in 5 patients on TSH suppression therapy who were TRH-unresponsive and one who had a minimal response to TRH. Thus, TRH-unresponsive patients did not secrete measurable amounts of TSH throughout the 24-h period. To suppress TSH secretion, all patients were treated with L-thyroxine (T4) at doses which resulted in undetectable TSH values in random plasma samples. TRH tests were carried out only when random TSH concentrations were <0.6 μU/ml. Seven of the 26 patients (27%) including two with thyroid cancer were TRH-responsive indicating a potential for TSH secretion. In these seven, the T4 dose was adjusted until they were TRH-unresponsive. The mean change in T4 dose of these 7 patients was 20 ± 10 (SD) μg/day and this resulted in a mean increase of 1.5 ± 1.1 μg/dl for T4 and 20 ± 20 ng/dl for T3. For all patients, the mean T4 dose required for TSH suppression was 172 ± 53 μg/day or 2.6 ± 0.8 μg per day per kg body weight. Twenty-three of 26 patients required between 100-200 μg/day and the remaining 3, 250-300 μg/day. The T4 dose required to suppress TSH resulted in normal serum concentrations of T4, 9.1 ± 2.0 μg/dl, and T3, 136.7 ± 33.6 ng/dl. These T4 doses did not produce a rapid heart rate, either awake or asleep, arrhythmias, or electrocardiographic abnormalities as assessed by 24-h Holter monitor tracings in 11 patients. Their results thus show that the T4 dose which results in an unresponsive TRH test ensures that serum TSH will remain undetectable (<0.6 μU/ml) throughout the 24-h period. An unresponsive r118w1.r128w2+ TRH test, therefore, appears to be a very useful and reliable index of TSH suppression.

AB - Most serum thyrotropin (TSH) assays do not adequately discriminate between normal values and absent TSH. The authors therefore evaluated the TSH response to thyrotropin releasing hormone (TRH) as a criterion for the adequacy of TSH suppression therapy. Twenty-six outpatients with various thyroid disorders (cancer, 10; nodules, 9; miscellaneous, 4; hypothyroidism after 131I therapy for Graves' disease, 3) were studied. Using the frequent sampling technique (samples every 20 min) in two normal volunteers and one untreated patient who was TRH-responsive, the authors first confirmed the observation that TSH secretion occurred episodically throughout the 24-h period. In contrast, serum TSH was undetectable (<0.6 μU/ml) throughout the 24-h period in 5 patients on TSH suppression therapy who were TRH-unresponsive and one who had a minimal response to TRH. Thus, TRH-unresponsive patients did not secrete measurable amounts of TSH throughout the 24-h period. To suppress TSH secretion, all patients were treated with L-thyroxine (T4) at doses which resulted in undetectable TSH values in random plasma samples. TRH tests were carried out only when random TSH concentrations were <0.6 μU/ml. Seven of the 26 patients (27%) including two with thyroid cancer were TRH-responsive indicating a potential for TSH secretion. In these seven, the T4 dose was adjusted until they were TRH-unresponsive. The mean change in T4 dose of these 7 patients was 20 ± 10 (SD) μg/day and this resulted in a mean increase of 1.5 ± 1.1 μg/dl for T4 and 20 ± 20 ng/dl for T3. For all patients, the mean T4 dose required for TSH suppression was 172 ± 53 μg/day or 2.6 ± 0.8 μg per day per kg body weight. Twenty-three of 26 patients required between 100-200 μg/day and the remaining 3, 250-300 μg/day. The T4 dose required to suppress TSH resulted in normal serum concentrations of T4, 9.1 ± 2.0 μg/dl, and T3, 136.7 ± 33.6 ng/dl. These T4 doses did not produce a rapid heart rate, either awake or asleep, arrhythmias, or electrocardiographic abnormalities as assessed by 24-h Holter monitor tracings in 11 patients. Their results thus show that the T4 dose which results in an unresponsive TRH test ensures that serum TSH will remain undetectable (<0.6 μU/ml) throughout the 24-h period. An unresponsive r118w1.r128w2+ TRH test, therefore, appears to be a very useful and reliable index of TSH suppression.

UR - http://www.scopus.com/inward/record.url?scp=0017646206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017646206&partnerID=8YFLogxK

M3 - Article

C2 - 404309

AN - SCOPUS:0017646206

VL - 44

SP - 892

EP - 901

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 5

ER -